linjc16/ctgov huggingface dataset:
Myocardial Function Assessment in Patients With Coronary Artery Disease Using Noninvasive Myocardial Work

Study Overview
=================
Brief Summary
-----------------
Noninvasive pressure-strain loop (PSL) derived myocardial work (MW) are more sensitive than conventional echocardiographic parameters in quantitative assessment of early myocardial dysfunction. The aim of this study was to assess left ventricular (LV) myocardial function in symptomatic patients with coronary artery disease using the promising method. Methods: Transthoracic echocardiography was performed on patients with angina or equivalent symptoms before coronary angiography. Images were stored and imported into the software for further offline analysis of PSL-based MW. MW analysis were carried out on each patient for global and regional myocardial function assessment.

Official Title
-----------------
Myocardial Function Assessment in Patients With Coronary Artery Disease Using Noninvasive Myocardial Work

Conditions
-----------------
Noninvasive Myocardial Work, Coronary Artery Disease

Intervention / Treatment
-----------------
* Diagnostic Test: Transthoracic echocardiography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who were hospitalized for coronary angiography with angina or equivalent symptoms. - Exclusion Criteria: Acute coronary syndrome, left main stem coronary disease, left ventricular ejection fraction (LVEF) below 55%, observed resting regional wall motion abnormalities (RWMAs), non-sinus rhythm, intraventricular block, previous cardiac surgery, severe valvular heart disease, hypertrophic cardiomyopathy, myocarditis, pericardial diseases, pulmonary hypertension, and poor image quality. -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| nonsignificant coronary artery stenosis group<br>Exclusion criteria: ≥70% proximal luminal stenosis in at least one major coronary vessel based on coronary angiography | Diagnostic Test: Transthoracic echocardiography<br>* noninvasive myocardial work<br>|
| significant coronary artery stenosis group<br>Defined as ≥70% proximal luminal stenosis in at least one major coronary vessel based on coronary angiography | Diagnostic Test: Transthoracic echocardiography<br>* noninvasive myocardial work<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| myocardial function | noninvasive myocardial work indices | baseline (before coronary angiography) |
Salvage Surgeries for Splanchnic Artery Aneurysms After Failed Endovascular Therapies: Cases Series

Study Overview
=================
Brief Summary
-----------------
A retrospective review was performed for consecutive patients (from 2019 to 2021) who underwent salvage surgeries following failed endovascular therapies for splanchnic artery aneurysms in a tertiary referral center. Salvage operations include total aneurysmectomy with vascular reconstruction and partial aneurysmectomy with directly closing bleeders from the intraluminal space of the aneurysms.

Detailed Description
-----------------
Salvage surgery for splanchnic artery aneurysm after failed endovascular trials includes one of the following three strategies: (1) aneurysmectomy along with the involved organ if the aneurysm is located within the parenchyma of solid organs (2) aneurysmectomy with vascular reconstruction if the aneurysm outside the solid organ (3)partial aneurysmectomy with direct closing the feeding vessel orifice if the aneurysm occurs in the hostile abdomen.

Official Title
-----------------
Salvage Surgeries for Splanchnic Artery Aneurysms After Failed Endovascular Therapies: Cases Series

Conditions
-----------------
Mass Effect, Failure in Endovascular Therapy, Splanchnic Aneurysm, Surgery

Intervention / Treatment
-----------------
* Procedure: Aneurysmectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients underwent salvage surgeries following failed endovascular therapies for splanchnic artery aneurysms The aneurysms were diagnosed based on medical history and computed tomography (CT) Exclusion Criteria: Patients only underwent endovascular therapies for artery aneurysms The aneurysms are not located at the splanchnic artery
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Aneurysmectomy|Complete aneurysmectomy with end-to-end anastomosis for the true aneurysm or partial aneurysmectomy with a direct repair.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Survival outcomes after surgical intervention | Survival outcomes (i.e., overall survival and symptoms-free survival in months) after salvage surgery for the splanchnic aneurysms were collected based on chart reviewing and telephone calls. | From surgical intervention to the latest follow-up date (i.e., 2023-Jan-20) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
salvage surgery, failed endovascular therapy, giant aneurysm, mass effect, jaundice, surgery
Testosterone and Vascular Function in Reproductive-Aged Females With Chronic Kidney Disease

Study Overview
=================
Brief Summary
-----------------
Cardiovascular disease (CVD) is the leading cause of death among women and women with chronic kidney disease are at an even greater risk of CVD. The aim of this observational study is to examine the relationship between total testosterone levels and measures of vascular function (pulse wave velocity, aortic augmentation index, flow mediated dilation and velocity time integral) in reproductive-aged women living with chronic kidney disease.

Official Title
-----------------
Testosterone and Vascular Function in Reproductive-Aged Females With Chronic Kidney Disease

Conditions
-----------------
Chronic Kidney Diseases, Cardiovascular Diseases

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: female sex a diagnosis of chronic kidney disease or end stage kidney disease age 18-51 Exclusion Criteria: Pregnancy, breastfeeding, current use of menopausal hormone therapy or gender affirming hormone therapy, or factors that would affect ovarian function, such as polycystic ovarian syndrome, premature ovarian insufficiency, ovarian malignancy, gonadotoxic chemotherapy, surgical oophorectomy, or previous radiation to the pelvis.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 51 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pulse wave velocity |  | Measured at baseline | 
| Aortic augmentation index |  | Measured at baseline | 
| Flow mediated dilation |  | Measured at baseline | 
| Velocity time integral |  | Measured at baseline |
To Evaluate the Safety and the Pharmacokinetics of NVP-2203

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the safety and pharmacokinetics after administration of NVP-2203.

Detailed Description
-----------------
Phase 1 to evaluate the safety and pharmacokinetics after administration of NVP-2203.

Official Title
-----------------
Phase 1 Study to Evaluate the Safety and the Pharmacokinetics of NVP-2203 in Healthy Adult Volunteers

Conditions
-----------------
Healthy Volunteers

Intervention / Treatment
-----------------
* Drug: NVP-2203
* Drug: NVP-2203-R


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy adult subjects who signed informed consent BMI of >18.0 kg/m2 and <30.0 kg/m2 subject, weight more than 50kg(45 kg or more for woman) Exclusion Criteria: Subjects participated in another clinical trial within 6 months prior to administration of the study drug Inadequate subject for the clinical trial by the investigator's decision

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: NVP-2203<br>After fasting (except water) for at least 10 hours before dosing, oral administration of investigational product once daily on Period 1(or Period 2) | Drug: NVP-2203<br>* NVP-2203(Combination of NVP-2203-R1 and NVP-2203-R2)<br>|
| Active Comparator: NVP-2203-R<br>After fasting (except water) for at least 10 hours before dosing, oral administration of investigational product once daily on Period 1(or Period 2) | Drug: NVP-2203-R<br>* administration of active comparator<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| NVP-2203's pharmacokinetics of plasma | AUCt | 0hours - 72hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pharmacokinetics of plasma | Cmax | 0hours - 72hours |
Incidence of Metabolic Disorders in Neonatal Convulsions

Study Overview
=================
Brief Summary
-----------------
Describe the incidence of metabolic disorders in neonatal convulsions affecting neonates at NICU Describe types of metabolic disorders causing neonatal convulsions

Detailed Description
-----------------
Neonates are susceptible to seizures due to several physiologic factors and combination of risks that are uniquely associated with gestation, delivery,and the immediate postnatal period. Neonatal seizures can be challenging to identify therefore itis imperative that clinicians have ahigh degree of suspicion for seizures based on the clinical history or the presence of encephalopathy with or without paroxysmal abnormal movements. Acute symptomatic neonatal seizures are due to an acute brain injury, whereas neonatal onset_epilepsy may be due to underlying structural, metabolic ,or genetic disorders.Early identification and treatment are likely important for long term outcomes in acute symptomatic seizures though additional studies are needed to understand optimal seizure control metrics and the ideal duration of treatment. seizures may be the first and the major presenting feature of an inborn error of metabolism. seizures may be preceded by other major symptoms by areduced level of consciousness in achild with an organic acidemia or urea cycle defect or by loss of skills ,progressive weakness ,ataxia ,and upper motor signs in achild with lysosomal storage disorder or peroxisomal leukodystrophy.the metabolic causes of seizure vary according to age at presentation.

Official Title
-----------------
Adescriptive Study on Incidence of Metabolic Disorders in Neonatal Convulsions

Conditions
-----------------
Neonatal Convulsions

Intervention / Treatment
-----------------
* Device: MRI


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Neonatal convulsions associated with vomiting,acidotic breathing,DCL,change of body tone or change in hair color Abnormal metabolic investigations (elevated serum ammonia and lactate ,persistent metabolic acidosis,abnormal metabolic screening and hypoglycemia persistent neonatal convulsions not respond to antiepileptic drugs Exclusion Criteria: History of neonatal asphyxia History of birth trauma Signs of sepsis and CNS infection Neonate with electrolyte disturbance

Ages Eligible for Study
-----------------
Minimum Age: 1 Day
Maximum Age: 28 Days

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: MRI|Investigations as CT,MRI.serum ammonia and lactate|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Describe incidence of metabolic disorders in neonatal convulsions affecting neonates at NICU | Describe types of metabolic disorders causing neonatal convulsions | Baseline |
Learning Excellence Program and Improvement of Quality Care

Study Overview
=================
Brief Summary
-----------------
Improving the quality of care is a daily goal in pediatric intensive care units. Measuring patient and family satisfaction is recognized as an indicator of quality of care. A validated questionnaire was specially developed to study parental satisfaction in pediatric intensive care units. A positive multi-professional analysis of clinical situations, using appreciative inquiry, within a health service can create new opportunities for learning and innovation. The establishment of such a Learning From Excellence (LfE) program tends to increase the well-being and self-confidence of caregivers and promotes dynamic learning educational programs, including simulation. It therefore seems important to assess the improvement in the quality of care in pediatric intensive care following the implementation of a Learning From Excellence program allowing positive reflection on practices as well as innovations within the service.

Official Title
-----------------
Improvement the Quality of Care Through the Implementation of a Learning From Excellence Program in a Pediatric Intensive Care Unit

Conditions
-----------------
Satisfaction, Patient

Intervention / Treatment
-----------------
* Other: Questionnaire


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All parents of children aged 0 to 18 who have been hospitalized in the pediatric intensive care unit over a period of 24 months once the research has been authorized and started Exclusion Criteria: Parents unable to answer the questionnaire because they do not speak French Parents of children who died during their stay in the pediatric intensive care unit

Ages Eligible for Study
-----------------
Minimum Age: 1 Day
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Experimental:children hospitalized in pediatric intensive care unit<br>All parents of children aged 0 to 18 who have been hospitalized in the pediatric intensive care unit over a period of 24 months will be offered the study. | Other: Questionnaire<br>* A questionnaire is offered to parents of patients who meet the eligibility criteria and who have given their non-objection. This questionnaire aims to evaluate the quality of care perceived by the parents of children hospitalized in the pediatric intensive care unit<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of the quality of care. | Satisfaction will be measured via the EMpowerment of Parents in THe Intensive Care questionnaire score (EMPATHIC-65 questionnaire) | Day 1, the day of discharge from hospital |
Evaluation of the Diagnostic and Prognostic Role of PET (PET/CT and PET/MRI) in Neuroendocrin Tumors.

Study Overview
=================
Brief Summary
-----------------
Neuroendocrine tumors (NETs) constitute approximately 0.5% of malignancies. To date, diagnosis at an increasingly early stage of the disease is possible thanks to recent technological advances in biomedical imaging. In particular, the traditional work-up for these pathologies includes endoscopy, magnetic resonance imaging (MRI) and computed tomography (CT). Furthermore, the integrated positron emission tomography methods (PET/CT and PET/MRI) are innovative molecular imaging techniques and represent a continually expanding field of research in the oncology setting. In particular, PET is taking on an increasingly relevant role for the study of neuroendocrine tumors, also thanks to the introduction of increasingly accurate radiopharmaceuticals (targeted towards somatostatin receptors), thus opening the way to new possibilities for the diagnosis andcharacterization of these tumors, is in the staging and restaging phase .

Official Title
-----------------
Evaluation of the Diagnostic and Prognostic Role of PET (PET/CT and PET/MRI) in Neuroendocrin Tumors.

Conditions
-----------------
Neuroendocrine Tumors

Intervention / Treatment
-----------------
* Diagnostic Test: diagnostic accuracy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients affected by neuroendocrine tumors; Patients who have performed at least one PET study with 18F-FDG and/or 68Ga- DOTATOC for the staging or diagnosis of their pathology. Exclusion Criteria: Patients < 18 years old; Lack of availability of clinical data and PET imaging useful for analyses.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: diagnostic accuracy|The aim of this retrospective study is to evaluate the diagnostic and prognostic value of PET/MRI and PET/CT with the use of different radiopharmaceuticals (68Ga-DOTATOC -edotreotide, and 18F-FDG - fluorodeoxyglucose) for the study of patients suffering from neuroendocrine tumors. To this end, both traditional imaging parameters and the contribution of radiomic features will be investigated. The latter are quantitative features extracted from biomedical images, and are believed to be able to provide information, otherwise impossible to investigate, useful for the characterization of various pathologies.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 800 patients suffering from neuroendocrine tumors who have undergone PET examination (PET/CT or PET/MRI) with 18F-FDG or 68Ga-DOTATOC. | The integrated positron emission tomography methods (PET/CT and PET/MRI) are innovative molecular imaging techniques, for the diagnosis and characterization of these tumors. | 2 years |
Phase 1 Trial in Patients With Human Papillomavirus (HPV)-Associated Cancer

Study Overview
=================
Brief Summary
-----------------
This is an open-label, non-randomized, Phase I, dose escalation/dose expansion study in cohorts of patients with relapsed, resistant, or metastatic HPV-associated cancers. The Expansion Phase will begin in parallel one dose level lower than the highest dose deemed safe in the Dose Escalation in combination with a PD-1 checkpoint blockade.

Official Title
-----------------
A Phase 1 Trial of TGN-S11 in Patients With Human Papillomavirus (HPV)-Associated Relapsed, Resistant or Metastatic Cancer

Conditions
-----------------
HPV Associated Cancers

Intervention / Treatment
-----------------
* Drug: TGN-S11
* Drug: Pembrolizumab


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Prior histologically confirmed HPV-associated squamous cell carcinoma, which is relapsed, resistant, or metastatic Life expectancy of at least 3 months Dose Escalation Phase: patients who have experienced disease progression on Standard of Care Therapies Exclusion Criteria: Active CNS metastases Have any history of seizure disorder or are taking prophylactic seizure medication Have an active viral, bacterial, or fungal infection

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: Phase I, dose escalation/dose expansion study. Expansion Phase will begin in parallel one dose level lower than the highest dose deemed safe in the Dose Escalation in combination with a PD-1 checkpoint blockade.
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Dose Escalation<br>To determine the MTD in patients with HPV-associated cancers | Drug: TGN-S11<br>* Small Molecule<br>|
| Experimental: Dose Expansion<br>Dose Expansion Phase, in parallel one dose level lower than the highest dose deemed safe in Dose escalation with a PD-1 checkpoint blockade. | Drug: TGN-S11<br>* Small Molecule<br>Drug: Pembrolizumab<br>* PD-1 checkpoint blockade<br>* Other names: Keytruda;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Maximum Tolerated Dose | To determine the maximum tolerated dose (MTD) of TGN-S11 in patients with human papillomavirus (HPV)-associated relapsed, resistant, or metastatic cancer. | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PK Parameters to determine the single dose | Cmax | 30 days | 
| Steady state pharmacokinetics (PK) of TGN-S11 | AUC | 30 days |